Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pediatric TRIUMEQ and DTG/3TC Formulations
NCT03441984Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir, abacavir and lamivudine in human immunodeficiency virus infection (HIV) (12 arms), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time of Dose Extrapolated to Infinity, Area Under the Plasma Concentration-time Curve From Time of Dose to Last Measurable Concentration and 1 more. Started Feb 2018; status: completed.
02
Drugs
dolutegravirabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03441984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441984.